// App-Quantinova.ai

: Pirfenidone in unclassifiable ILD (uILD: subgroup analysis of patients with/without a surgical lung biopsy (SLB

Researchers

Presenter

  • Vincent Cottin

Principal Investigators

  • Tamera J. Corte

  • Michael Kreuter

  • Maria Molina-Molina

  • Judit Axmann

  • Frank Gilberg

  • Klaus-Uwe Kirchgaessler

  • Toby M. Maher

Medical Centers

  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France,

  • Department of Respiratory Medicine, Royal Prince Alfred Hospital and Medical School, University of Sydney, Camperdown, New South Wales, Australia

  • Center for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg and German Center for Lung Research, Heidelberg, Germany

  • ILD Unit, University Hospital of Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital and Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, London, United Kingdom

Locations

  • France

  • Australia

  • Germany

  • Spain

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT03099187

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved